Anna Richo serves as executive vice president and general counsel for UCB, a biopharmaceutical firm focused on developing treatments for individuals with neurological and immunological disorders. A resident of Brussels, Anna Richo also belongs to the Institut des Juristes d’Entreprise, which offers members a number of educational seminars, including Antitrust Issues in the Digital Economy.
Hosted in collaboration with Crowell & Moring, Antitrust Issues in the Digital Economy will provide in-house counsels with up-to-date information and review with them pertinent legal proceedings, such as the German Asics case and the sector inquiry by the European Commission into European Union e-commerce. Speakers at the seminar will include representatives from the European Commission and partners from Crowell & Moring.
The seminar, which will be preceded by a networking lunch, will be held in Brussels on September 22, 2016, and members may register at no cost by September 19, 2016. To learn more about the seminar, visit IBJ.be.
Joining UCB in November 2012 as executive vice president and general counsel, Anna Richo previously held senior executive positions at other pharmaceutical and health care companies. The corporation that Anna Richo represents is listed by Forbes magazine on it Global 2000 List of companies.
Biopharmaceutical company UCB SA focuses on the fields of immunology and central nervous system disorders. It engages in research and development as well as commercialization of new drugs and solutions to help people suffering from severe diseases of the central nervous system or the immune system.
Its main immunology product is Cimzia, which is used to treat Crohn’s disease, axial spondyloarthritis, ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis. UCB’s main neurology products include Briviact, Vimpat, and Keppra, which are all used for the treatment of epilepsy, and Neupro, which is used to treat Parkinson’s disease and restless legs syndrome.
UCB reaches millions of patients around the world with its products and solutions. It has more than 7,500 employees globally and does business in around 40 countries. Listed on the Euronext, it generated revenues of €3.8 billion in 2015.
UCB was founded in 1928 and is based in Brussels, Belgium.
The executive vice president and general counsel for UCB, a biopharmaceutical company, Anna Richo is an experienced legal professional. Throughout her distinguished career, Anna Richo has given speeches at events hosted by many prestigious organizations, including the NAACP, the Young Lawyers Section of the Chicago Bar Association, and the California Healthcare Institute.
Giving a great speech at a large-scale event can seem intimidating, but the following three tips may help make the practice much easier.
1. Talk about what you know: Some speakers are preoccupied with making bold statements for the sake of impact, but the most impactful statements often come from talking to the audience about topics that you find personally relate to. Passion drives energy, and speeches that draw from personal experience can leave a much more lasting impression.
2. Look confident: The audience will be more likely to consider your points if you look self-assured. Maintain good posture and be sure to make eye contact with your audience.
3. Change up your speech patterns: Monotone speech is going to leave your audience feeling disengage. Practice your speech in advance, experimenting with different tones and deciding which words to emphasize. Additionally, don’t forget to practice slowing down the speed of your speech, as nervous orators tend to deliver speeches quickly.
While serving Amgen Inc. as a senior vice president and chief compliance officer, Anna Richo, JD, has 25 years’ experience in the pharmaceutical and biotechnology industry. Anna Richo was highlighted in an online article by the Minority Corporate Counsel Association for her achievements overseeing litigation for companies such as the Baxter Healthcare Corporation.
Founded in 1997, the Minority Corporate Counsel Association (MCCA) supports attorneys of minority backgrounds in corporate legal departments and law firms. The organization focuses on research and training to build awareness about its mission. In addition, it publishes Diversity & The Bar, a magazine distributed to Association members every two months.
Diversity & The Bar reaches more than 35,000 readers, most of whom are senior in-house legal advisors and attorneys. The readership is split nearly in half between genders. Among the topics discussed in 2015 were best practices for diversity professionals, the winners of the MCCA’s Rainmakers Award, and the recipients of the Lloyd M. Johnson Jr. Scholarship. In addition, the magazine published a feature article about rising stars in the corporate legal field.
As the executive vice president and general counsel for UCB in Brussels, Belgium, Anna Richo focuses on the company’s intellectual property, legal, and corporate compliance departments. Anna Richo utilizes more than 25 years of experience in the pharmaceutical industry to perform her work with the international biopharmaceutical company.
Dedicated to improving the quality of life for people around the world, UCB develops cutting-edge medications and maintains a corporate social responsibility program, which includes the UCB Societal Responsibility Fund. UCB founded the Fund in partnership with the King Baudouin Foundation, a well-known nonprofit organization in Belgium, to improve neurological care and quality of life for people with epilepsy and limited financial resources. By supporting a variety of initiatives worldwide, the Fund helps to grow awareness about epilepsy, improve diagnostic capabilities, promote acceptance for people with the disease, and increase health workers’ understanding of epilepsy.
The Fund awards grants to established organizations and primarily concentrates on two projects, Project HOPE in China – Rainbow Bridge and the Brothers of Charity in Rwanda and the Democratic Republic of Congo. Both projects strive to train neurologists and decrease social stigmas against people with epilepsy.
Anna Richo, a graduate of Cornell University and the DePaul University College of Law, has nearly 30 years’ experience as an attorney. Anna Richo currently serves as an executive vice president and general counsel at UCB in Brussels, Belgium, focusing on intellectual property law and corporate compliance.
The DePaul University College of Law offers students a number of unique juris doctor programs. Restorative justice is just one of the many areas of law individuals can focus on. As alternative dispute-resolution practices gain popularity throughout the United States, many legal professionals are looking into the field of restorative justice. While students will learn about the practice in depth, the process could be summarized as creating a safe environment in which ideas can be exchanged, conflicts addressed, and forgiveness achieved.
Asylum and immigration law is another doctoral area of study at DePaul University College of Law. The school’s Asylum & Immigration Law Clinic provides hundreds of immigrants with legal support every year, which gives law students the perfect setting in which to learn. Students can also choose to focus on business law and taxation, child and family law, intellectual property law, and much more.
A former executive of Amgen, Inc., in 2012, Anna Richo joined UCB, a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions related to severe diseases of the immune system or of the central nervous system. A member of the UCB executive committee, Anna Richo performs duties as executive vice president and general counsel for the company and oversees all aspects of legal and corporate compliance.
In April 2014, UCB released the results of its Policy for Optimal Epilepsy Management (POEM) study. The study included 249 United States veterans who used the health data sharing network PatientsLikeMe for the first time. During the study, the participants connected with other patients on the site and had access to condition-specific tracking tools and educational resources. At the end of the six-week period, the participants completed an epilepsy self-management scale (ESMS) and an epilepsy self-efficacy scale (ESES), which was compared to their evaluations taken prior to the start of the study. Of the individuals, approximately 37 percent completed the assessments and showed an improvement in managing their epilepsy. ESMS increased from 140 to 143 and ESES jumped 10 points.
The results of this study indicate that when epilepsy patients interact with one another, their conditions improve. Further, the study was conducted in a relatively short time frame, showing that patients do not have to spend years adapting to online technology to benefit from it.